Could a novel noninvasive gastric mapping device that measures stomach activity offer new insights into chronic nausea and vomiting? (Science Translational Medicine)
Vedolizumab (Entyvio) and ustekinumab (Stelara) were both highly effective as third-line biologics in induction and maintenance for Crohn’s disease, an observational Italian study found. (Digestive and Liver Disease)
What are the best foods to feed your gut? (Washington Post)
Fecal microbiota transplantation as a first-line treatment for an initial or second Clostridioides difficile infection was superior to standard of care vancomycin for sustained resolution of diarrhea at 8 weeks, a small randomized trial found. (The Lancet Gastroenterology & Hepatology)
Low cortisol concentrations predicted better chances of 28-day transplant-free survival for patients with adrenal insufficiency in acute and acute-on-chronic liver failure, according to European researchers. (Gastro Hep Advances)
The diuretic spironolactone showed promise as a potential treatment for alcohol use disorder. (National Institutes of Health, Molecular Psychiatry)
Perianal Crohn’s disease was common among colorectal and anal cancer patients, according to a meta-analysis. (Journal of Crohn’s and Colitis)
Non-alcoholic fatty liver disease patients who did not meet the criteria for metabolic-associated fatty liver disease were more likely to develop metabolic syndrome than were those without either type of fatty liver disease, a South Korean study found. (Clinical Gastroenterology and Hepatology)
A score based on lab test results over the preceding year predicted future intestinal complications in patients with Crohn’s disease, which could provide a rational for earlier escalation of therapy. (Digestive Diseases and Sciences)
Source: MedicalNewsToday.com
